Argá Medtech SA

This week at the Stanford Biodesign New Arrhythmia Technologies Retreat, Argá Medtech presented its Coherent Sinewave Electroporation platform, a pioneering treatment for Atrial Fibrillation and other cardiac arrhythmias. Our CEO, David Neale, provided an insightful update on the BURST-AF study, highlighting that out of 54 patients treated, 18 have completed a 12-month follow-up, with 16 patients (88.9%) experiencing freedom from AF and other arrhythmias. As we gear up for the IDE study slated for early 2025, we're actively seeking partnership centers to join us on this groundbreaking journey. The first-in-human study by Argá Medtech has been a resounding success, enrolling 54 patients to date and showcasing promising results that promise to revolutionize arrhythmia management and patient care. Our ALL-in-ONE catheter allows for the treatment of Paroxysmal and Persistent AF without the need of using a second catheter. Simplicity at its best, the efficiency of a single-shot device with the flexibility of a linear/ focal catheter. We are thrilled to be at the forefront of cardiac health innovation. Our heartfelt thanks go to: - The Event Organizers for facilitating a retreat that sparks knowledge sharing and expert collaboration. - Our Argá Medtech team, whose relentless dedication has been the driving force behind our technological breakthroughs. - Our investors, whose unwavering trust has been instrumental in our journey. - The Enrollment Center Staff, whose commitment to patient care is the backbone of our progress. Argá Medtech is steadfast in its mission to enhance arrhythmia treatments. We invite you to follow our continued progress as we forge ahead with medical advancements that hold the promise of bettering patient lives. #StanfordBiodesign #ArrhythmiaTherapy #MedicalInnovation #PFA ##pusledfieldablation #cardiacablation #AtrialFibrillation, #EP, #EPeeps, #Electrophysiology Argá Medtech SA Randy Werneth, Micah Lee, Mark Zurcher, Brandon Lee, John Yianni Shahzad Malik Henry Zubaida Janke Dittmer HTGF | High-Tech Gründerfonds Biopôle Lausanne Earlybird Venture Capital Gilde Healthcare Advent Life Sciences WexMed II LLC, HBM-Medfocus LLC Ante Anic, Giorgi Papiashvili, Melvin Lorenzo

Argá Medtech SA to present its latest data at the Stanford Biodesign New Arrhythmia Technologies Retreat. May 15th, Boston. https://lnkd.in/efXzMtyG

We are pleased to share that we closed a €54M oversubscribed Series B raise to advance the clinical studies of our innovative pulsed field ablation system for treating #atrialfibrillation. The financing will enable us to validate the early clinical results for our Coherent Sine-burst Electroporation™ (CSE™) ablation technology through the execution of an IDE study in the US and a CE Mark study in the EU. To learn more, read our full press release: https://lnkd.in/dvvaR54j Earlybird Venture Capital Advent Life Sciences Gilde Healthcare #PFA #cardiacablation #argamedtech #epeeps #electrophysiology

Earlier today, Dr. Ante Anic presented groundbreaking data at AF Symposium 24 on the Argá Medtech Coherent Sine-burst Electroporation (CSE) ablation system. The team's hard work and dedication to developing this disruptive technology over the past 3 years culminated in the treatment of 48 patients with outstanding results. The data presented demonstrated the efficacy and flexibility of the technology, setting it apart from others in the field. Congratulations to the team on this incredible achievement! #AFSymposium24 #disruptivetechnology #medicaladvancements #epeeps #pfa #cardiology #electrophysiology Randy Werneth Earlybird Venture Capital Shahzad Malik Elena Marchesi John Yianni Micah Lee Melvin Lorenzo David Neale Biopôle Lausanne

Strong start for 2024! Moved to new facilities to support our future. We continue to make good and rapid progress with our Coherent Sine-burst Electroporation system, outgrowing our facilities. @David Neale @Randy Werneth Earlybird Venture Capital #pfa #epeeps https://lnkd.ineVHNDzrJ